๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

An evaluation of bicalutamide in the treatment of prostate cancer

โœ Scribed by Schellhammer, Paul F

Book ID
121872480
Publisher
Informa plc
Year
2002
Tongue
English
Weight
282 KB
Volume
3
Category
Article
ISSN
1465-6566

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Bicalutamide dosages used in the treatme
Bicalutamide dosages used in the treatment of prostate cancer
โœ Kolvenbag, Geert J.C.M.; Nash, Anthony ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 200 KB ๐Ÿ‘ 2 views

## BACKGROUND. Androgen deprivation is often used for the treatment of patients with prostate cancer. Androgen deprivation can be achieved by surgical castration or medical castration, with or without using an antiandrogen. Each of these treatments may be used alone, or an antiandrogen may be used

Bicalutamide (Casodexยฎ) in the treatment
Bicalutamide (Casodexยฎ) in the treatment of prostate cancer: History of clinical development
โœ Kolvenbag, Geert J.C.M.; Blackledge, George R.P.; Gotting-Smith, Karen ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB ๐Ÿ‘ 1 views

BACKGROUND. Bicalutamide (Casodex) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate cancer have been evaluated in randomized clinical tria